Early Detection and Strategies for Overcoming Therapy Resistance in Lung Cancer and Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 37
Special Issue Editor
Interests: lung cancer; molecular profiling; precision medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Early detection and overcoming therapy resistance in lung cancer and mesothelioma are fundamental cornerstones for improving patient outcomes.
We welcome high-quality manuscripts exploring early detection strategies, including screening approaches, biomarker research and improved molecular diagnostics for lung cancer and mesothelioma. Overcoming resistance involves strategies such as targeting specific molecular pathways and immune responses, and exploring combinatory approaches and novel delivery systems for anti-cancer drugs.
Understanding the mechanisms of primary and acquired resistance to targeted therapies is crucial for selecting subsequent treatments. Equally important is understanding the tumour microenvironment and its influence on therapy resistance, which is essential for developing effective therapeutic strategies.
Effective management of lung cancer and mesothelioma requires a multidisciplinary approach, involving pathologists, surgeons, medical oncologists, radiation oncologists and other specialists. We encourage interdisciplinary and biomarker-driven clinical trials, which are essential for advancing treatment options and overcoming resistance in both lung cancer and mesothelioma.
Prof. Dr. Katalin Dobra
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- mesothelioma
- screening
- biomarker
- molecular diagnostics
- resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
